Sanofi bets $425M cash on a trans­for­ma­tion-style next-gen vac­cine deal — as the Big Phar­ma team makes a point

Back at the end of last March, with the world lock­ing down in the face of a pan­dem­ic, Sanofi tied up with mR­NA biotech Trans­late Bio an a hasti­ly patched-up Covid-19 deal that came with no mon­ey down on top of their orig­i­nal pact.

Now, as new Sanofi CEO Paul Hud­son plants the cor­po­rate flag on a quest to do a makeover of their slow-mo cor­po­rate im­age (see re­lat­ed sto­ry), Sanofi widened its em­brace with an­oth­er add-on: And this one comes with the con­sid­er­able panache of a big up­front to cov­er a next-gen drug tech­nol­o­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER